KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medpace Holdings (MEDP) EBITDA Margin (2016 - 2025)

Medpace Holdings (MEDP) has disclosed EBITDA Margin for 11 consecutive years, with 22.61% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 209.0% year-over-year to 22.61%, compared with a TTM value of 79.35% through Dec 2025, up 5684.0%, and an annual FY2025 reading of 22.22%, down 29.0% over the prior year.
  • EBITDA Margin was 22.61% for Q4 2025 at Medpace Holdings, down from 24.7% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 24.7% in Q4 2024 and bottomed at 16.67% in Q2 2021.
  • Average EBITDA Margin over 5 years is 20.35%, with a median of 20.68% recorded in 2022.
  • The sharpest move saw EBITDA Margin crashed -340bps in 2021, then soared 589bps in 2024.
  • Year by year, EBITDA Margin stood at 19.13% in 2021, then increased by 8bps to 20.68% in 2022, then fell by -9bps to 18.81% in 2023, then skyrocketed by 31bps to 24.7% in 2024, then fell by -8bps to 22.61% in 2025.
  • Business Quant data shows EBITDA Margin for MEDP at 22.61% in Q4 2025, 24.7% in Q4 2024, and 22.39% in Q3 2024.